ArticleNature neuroscience2023
Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN).
Abstract read
In one paragraph
Article in Nature neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Etalanetug (E2814) in dominantly inherited Alzheimer's disease: an open-label phase 1b/2 study to assess safety and target engagement in participants with mild to moderate cognitive impairment.Alzheimer's research & therapy · 2026Trial
- Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.Nature medicine · 2025Trial
- Multi-dimensional attention framework for personalised Alzheimer's disease progression prediction across sporadic and genetic risk cohorts.Research square · 2026Article
- Normalization method for relative cerebral blood flow influences sex and cognitive status effects in nondemented older adults.Brain imaging and behavior · 2026Article
- SPECT and PET imaging of Alzheimer's disease revisited: from biomarkers to artificial intelligence-based prediction.Annals of nuclear medicine · 2026Review
- Effect of Cognitive Reserve on Age at Symptom Onset and Cognitive Decline in Individuals With Dominantly Inherited Alzheimer Disease.Neurology · 2026Article
- Review
- Cognition, Diagnosis, and Treatment of Alzheimer's Disease: A Review.Recent patents on biotechnology · 2026Review
- 15 years of longitudinal genetic, clinical, cognitive, imaging, and biochemical measures in DIAN.NPJ dementia · 2026Article
- Plasma levels of an N-terminal tau fragment predict Alzheimer's and neurodegenerative disease biomarkers in autosomal dominant Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Cross-Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease.Annals of neurology · 2025Article
- The Knight Alzheimer Research Imaging (KARI) dataset: a comprehensive multimodal resource for exploring aging, preclinical, and symptomatic Alzheimer disease pathology.Research square · 2025Article
- Clinical ultrasound, photoacoustic, and fluorescence image-guided lymphovenous anastomosis microsurgery via a transparent ultrasound transducer array.Nature communications · 2025Article
- Proteomic analysis of Down syndrome cerebrospinal fluid compared to late-onset and autosomal dominant Alzheimer´s disease.Nature communications · 2025Article
- Ubiquitin-proteasome system in the different stages of dominantly inherited Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia.Nature medicine · 2025Article
- Early increase of the synaptic blood marker β-synuclein in asymptomatic autosomal dominant Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Prasinezumab slows motor progression in Parkinsons disease: beyond the clinical data.NPJ Parkinson's disease · 2025Review
- Article
- Elevated locus coeruleus metabolism provides resilience against cognitive decline in preclinical Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
- Commented on by
Authors and funding
65 authors.
Nicole S McKayWashington University in St. Louis, St. Louis, MO, USA.ORCID 0000-0003-4123-2548
Brian A GordonWashington University in St. Louis, St. Louis, MO, USA.ORCID 0000-0003-2109-2955
Russ C HornbeckWashington University in St. Louis, St. Louis, MO, USA.
Aylin DincerWashington University in St. Louis, St. Louis, MO, USA.
Shaney FloresWashington University in St. Louis, St. Louis, MO, USA.ORCID 0000-0003-2726-8704
Sarah J KeefeWashington University in St. Louis, St. Louis, MO, USA.
Nelly Joseph-MathurinWashington University in St. Louis, St. Louis, MO, USA.ORCID 0000-0002-9735-5152
Clifford R JackMayo Clinic, Rochester, MN, USA.ORCID 0000-0001-7916-622X
Robert KoeppeUniversity of Michigan, Ann Arbor, MI, USA.
Peter R MillarWashington University in St. Louis, St. Louis, MO, USA.ORCID 0000-0003-4588-739X
Beau M AncesWashington University in St. Louis, St. Louis, MO, USA.
Charles D ChenWashington University in St. Louis, St. Louis, MO, USA.ORCID 0000-0001-6698-1268
Alisha DanielsWashington University in St. Louis, St. Louis, MO, USA.
Diana A HobbsWashington University in St. Louis, St. Louis, MO, USA.ORCID 0000-0001-7822-6411
Kelley JacksonWashington University in St. Louis, St. Louis, MO, USA.
Deborah KoudelisWashington University in St. Louis, St. Louis, MO, USA.
Parinaz MassoumzadehWashington University in St. Louis, St. Louis, MO, USA.
Austin McCulloughWashington University in St. Louis, St. Louis, MO, USA.
Michael L NickelsWashington University in St. Louis, St. Louis, MO, USA.
Farzaneh RahmaniWashington University in St. Louis, St. Louis, MO, USA.
Laura SwisherWashington University in St. Louis, St. Louis, MO, USA.
Qing WangWashington University in St. Louis, St. Louis, MO, USA.
Ricardo F AllegriInstitute of Neurological Research Fleni, Buenos Aires, Argentina.ORCID 0000-0001-7166-1234
Sarah B BermanUniversity of Pittsburgh, Pittsburgh, PA, USA.
Adam M BrickmanColumbia University Irving Medical Center, New York, NY, USA.
William S BrooksNeuroscience Research Australia, Sydney, New South Wales, Australia.ORCID 0000-0001-8603-4233
David M CashUK Dementia Research Institute at University College London, London, UK.ORCID 0000-0001-7833-616X
Jasmeer P ChhatwalMassachusetts General and Brigham & Women's Hospitals, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-7792-1698
Gregory S DayMayo Clinic, Jacksonville, FL, USA.ORCID 0000-0001-5133-5538
Martin R FarlowIndiana University School of Medicine, Bloomington, IN, USA.
Christian la FougèreDepartment of Radiology, University of Tübingen, Tübingen, Germany.ORCID 0000-0001-7519-0417
Nick C FoxUK Dementia Research Institute at University College London, London, UK.
Michael FulhamRoyal Prince Alfred Hospital, Sydney, New South Wales, Australia.ORCID 0000-0003-0602-6319
Bernardino GhettiIndiana University School of Medicine, Bloomington, IN, USA.ORCID 0000-0002-1842-8019
Neill Graff-RadfordMayo Clinic, Jacksonville, FL, USA.
Takeshi IkeuchiNiigata University, Niigata, Japan.ORCID 0000-0001-8828-8085
William KlunkUniversity of Pittsburgh, Pittsburgh, PA, USA.
Jae-Hong LeeAsan Medical Center, Seoul, South Korea.
Johannes LevinGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Ralph MartinsEdith Cowan University, Joondalup, Western Australia, Australia.
Colin L MastersUniversity of Melbourne, Melbourne, Victoria, Australia.
Jonathan McConathyUniversity of Alabama at Birmingham, Birmingham, AL, USA.
Hiroshi MoriOsaka City University, Osaka, Japan.
James M NobleColumbia University Irving Medical Center, New York, NY, USA.
Gerald ReischlDepartment of Radiology, University of Tübingen, Tübingen, Germany.
Christopher RoweUniversity of Melbourne, Melbourne, Victoria, Australia.
Stephen SallowayBrown University. Butler Hospital, Providence, RI, USA.ORCID 0000-0002-2631-0942
Raquel Sanchez-ValleAlzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
Peter R SchofieldNeuroscience Research Australia, Sydney, New South Wales, Australia.ORCID 0000-0003-2967-9662
Hiroyuki ShimadaOsaka City University, Osaka, Japan.
Mikio ShojiHirosaki University, Hirosaki, Japan.
Yi SuBanner Alzheimer's Institute, Phoenix, AZ, USA.ORCID 0000-0002-1946-8063
Kazushi SuzukiUniversity of Tokyo, Tokyo, Japan.
Jonathan VögleinGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.ORCID 0000-0002-5965-838X
Igor YakushevSchool of Medicine, Technical University of Munich, Munich, Germany.
Carlos CruchagaWashington University in St. Louis, St. Louis, MO, USA.ORCID 0000-0002-0276-2899
Jason HassenstabWashington University in St. Louis, St. Louis, MO, USA.
Celeste KarchWashington University in St. Louis, St. Louis, MO, USA.ORCID 0000-0002-6854-5547
Eric McDadeWashington University in St. Louis, St. Louis, MO, USA.ORCID 0000-0002-6764-3866
Richard J PerrinWashington University in St. Louis, St. Louis, MO, USA.ORCID 0000-0002-3443-7716
Chengjie XiongWashington University in St. Louis, St. Louis, MO, USA.
John C MorrisWashington University in St. Louis, St. Louis, MO, USA.
Randall J BatemanWashington University in St. Louis, St. Louis, MO, USA.ORCID 0000-0002-7729-1702
Tammie L S BenzingerWashington University in St. Louis, St. Louis, MO, USA. benzingert@wustl.edu.ORCID 0000-0002-8114-0552
Dominantly Inherited Alzheimer Network
Funding
Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI MONICA G. RIVERA-MINDT · 2016 to 2026
$226.7MDIAN-TU Primary Prevention Trial NfL Characterization Admin SuppU01AG059798 · NIA · WASHINGTON UNIVERSITY · PI MCDADE, ERIC MARTIN · 2018 to 2025
$97.9MWU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8MDIAN-TU: Tau Next Generation Prevention Trial - Administrative SupplementR01AG068319 · NIA · WASHINGTON UNIVERSITY · PI RANDALL J BATEMAN · 2020 to 2026
$81.4MSmartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2026
$69.5MVascular Moderators of the Impact of Alzheimer's Pathology in the Young-OldP01AG025204 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HOWARD J AIZENSTEIN, Ann D. Cohen · 2005 to 2026
$56.5MImaging CoreU19AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2010 to 2025
$53.9MThe natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 2005 to 2025
$49.5MDIAN-TU Next Generation Prevention Trial - Data Request Management SupplementR01AG053267 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2017 to 2023
$34.9MResearch Education CoreP30AG066462 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PHILIP L DE JAGER · 2020 to 2026
$30.1MResearch Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI Susan Lynn Stark · 2020 to 2026
$28.7MDominantly Inherited Alzheimer's Network Trials Unit - Adaptive Prevention TrialR01AG046179 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2014 to 2019
$26.6MMedical Research Council MR/009076/1Medical Research Council MR/L023784/1NCATS NIH HHS UL1 TR002345NIA NIH HHS K01 AG080123NIA NIH HHS K23 AG064029NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG025204NIA NIH HHS P01 AG026276NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066462NIA NIH HHS P30 AG072980NIA NIH HHS R01 AG046179NIA NIH HHS R01 AG052550NIA NIH HHS R01 AG053267NIA NIH HHS R01 AG054567NIA NIH HHS R01 AG057840NIA NIH HHS R01 AG058676NIA NIH HHS R01 AG059798NIA NIH HHS R01 AG061900NIA NIH HHS R01 AG068319NIA NIH HHS R01 AG074909NIA NIH HHS R03 AG072375NIA NIH HHS R13 AG055232NIA NIH HHS R56 AG053267NIA NIH HHS RF1 AG073424NIA NIH HHS RF1 AG079569NIA NIH HHS T32 AG058518NIA NIH HHS U01 AG042791NIA NIH HHS U01 AG059798NIA NIH HHS U19 AG024904NIA NIH HHS U19 AG032438NIA NIH HHS UF1 AG032438NIH HHS S10 OD025214
Abstract
The Dominantly Inherited Alzheimer Network (DIAN) is an international collaboration studying autosomal dominant Alzheimer disease (ADAD). ADAD arises from mutations occurring in three genes. Offspring from ADAD families have a 50% chance of inheriting their familial mutation, so non-carrier siblings can be recruited for comparisons in case-control studies. The age of onset in ADAD is highly predictable within families, allowing researchers to estimate an individual's point in the disease trajectory. These characteristics allow candidate AD biomarker measurements to be reliably mapped during the preclinical phase. Although ADAD represents a small proportion of AD cases, understanding neuroimaging-based changes that occur during the preclinical period may provide insight into early disease stages of 'sporadic' AD also. Additionally, this study provides rich data for research in healthy aging through inclusion of the non-carrier controls. Here we introduce the neuroimaging dataset collected and describe how this resource can be used by a range of researchers.
Indexed as
Alzheimer DiseaseArthrogryposisAmyloid beta-PeptidesHumansMagnetic Resonance ImagingMutationNeuroimagingPositron-Emission TomographyAmyloid beta-Peptides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.